277 related articles for article (PubMed ID: 31212945)
1. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.
García-Carro C; Vergara A; Agraz I; Jacobs-Cachá C; Espinel E; Seron D; Soler MJ
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212945
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
3. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
Stephens JW; Brown KE; Min T
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis 101: diabetic kidney disease.
Lerma EV
Clin Kidney J; 2022 Oct; 15(10):1797-1799. PubMed ID: 36158143
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
8. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents.
Gnudi L; Karalliedde J
Nephrol Dial Transplant; 2016 Jul; 31(7):1036-43. PubMed ID: 25858586
[TBL] [Abstract][Full Text] [Related]
9. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
10. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.
Mittal N; Sehray V; Mittal R; Singh S
Eur J Pharmacol; 2021 Sep; 907():174320. PubMed ID: 34246651
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
[TBL] [Abstract][Full Text] [Related]
12. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath K; Edi R
Am Fam Physician; 2019 Jun; 99(12):751-759. PubMed ID: 31194487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.
Mallik R; Chowdhury TA
Ther Adv Endocrinol Metab; 2022; 13():20420188221081601. PubMed ID: 35281302
[TBL] [Abstract][Full Text] [Related]
14. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
Karalliedde J; Winocour P; Chowdhury TA; De P; Frankel AH; Montero RM; Pokrajac A; Banerjee D; Dasgupta I; Fogarty D; Sharif A; Wahba M; Mark PB; Zac-Varghese S; Patel DC; Bain SC
Diabet Med; 2022 Apr; 39(4):e14769. PubMed ID: 35080257
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century.
Alicic R; Nicholas SB
Mayo Clin Proc; 2022 Oct; 97(10):1904-1919. PubMed ID: 36202498
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
18. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
[TBL] [Abstract][Full Text] [Related]
19. Diabetic kidney disease treatment: new perspectives.
Tong LL; Adler SG
Kidney Res Clin Pract; 2022 Sep; 41(Suppl 2):S63-S73. PubMed ID: 36239062
[TBL] [Abstract][Full Text] [Related]
20. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
